No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT)

Radiotherapy and Oncology

Volumn 113, Issue 2, 2014, Pages 223-229

  Sainato, Aldo ^a   Cernusco Luna Nunzia, Valentina ^a   Valentini, Vincenzo ^b   De Paoli, Antonino ^c   Maurizi, Enrici Riccardo ^d   Lupattelli, Marco ^e   Aristei, Cynthia ^e   Vidali, Cristiana ^f   Conti, Monica ^g   Galardi, Alessandra ^h   Ponticelli, Pietro ⁱ   Friso, Maria Luisa ^j   Iannone, Tiziana ^k   Osti, Falchetto Mattia ^d   Manfredi, Bruno ^a   Coppola, Marianna ^l   Orlandini, Cinzia ^a   Cionini, Luca ^l  

^a UNIVERSITY OF PISA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF TRIESTE   (Italy)

^g Hospital of Venice   (Italy)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ Hospital of Arezzo   (Italy)

^j VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^k Hospital of Belluno   (Italy)

^l Centro Oncologico Fiorentino   (Italy)

more..

Author keywords

Adjuvant chemotherapy; Preoperative radiochemotherapy; Rectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; HUMAN; LOCALLY ADVANCED CANCER OF THE RECTUM; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; CHEMORADIOTHERAPY; CLINICAL TRIAL; FEMALE; MALE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RECTAL NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84915768105     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.10.006     Document Type: Article

References (41)

1. J.F. Bosset, L. Collette, and G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer New Engl J Med 355 2006 1114 11123
2. J.P. Gérard, T. Conroy, and F. Bonnetain Preoperative radiotherapy with or without concurrent flurouracil and Leucovorin in T3-4 rectal cancers: results of FFCD 9203 J Clin Oncol 24 2006 4620 4625
3. R. Sauer, H. Becker, and W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
4. D. Sebag-Montefiore, R.J. Stephens, and R. Steele Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentric randomized trial Lancet 373 2009 811 820
5. K. Bujko, M.P. Nowacki, and A. Nasierowska-Guttmejer Long term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer Br J Surg 93 2006 1215 1223
6. V. Valentini, P. Lambin, and R.J. Myerson Is it time for tailored of rectal cancer? From prescribing by consensus to prescribing by numbers Radiother Oncol 102 2012 1 3
7. V. Valentini, C. Aristei, and B. Glimelius Multidisciplinary rectal cancer management: 2nd European rectal cancer consensus conference (EURECACC2) Radiother Oncol 92 2009 148 163
8. QUASAR Collaborative Group Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study Lancet 370 2007 2020 2029
9. R.L. Li Combination of surgery, radiotherapy and chemotherapy for rectal cancer - a 423 cases report Zhonghua Zhong Liu Za Zhi Chin J Oncol 14 1992 213 215
10. R.G. Van Stiphout, G. Lammering, and J. Buijsen Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging Radiother Oncol 98 2011 126 133
11. J. Gaedcke, M. Grade, and K. Jung KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy Radiother Oncol 94 2010 76 81
12. A. Krzysztof Bujko, and Milena Kolodziejczyk Tumour regression grading in patients with residual rectal cancer after preoperative chemoradiation Radiother Oncol 95 2010 298 302
13. H.A.M. Swellengrebel, S.L. Bosch, and A. Cats Tumor regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathological complete response does not translate into good clinical outcome Radiother Oncol 112 2014 44 51
14. V. Valentini, R.G. van Stiphout, and G. Lammering Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials J Clin Oncol 29 2011 3163 3172
15. K. Bujko, R. Glynne-Jones, and M. Bujko Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials Ann Oncol 21 2010 1743 1750
16. C. Rodel, T. Liersch, and H. Becker Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal caner: initial results of the German CAO/ARO/AIO-04 randomized phase 3 trial Lancet Oncol 13 2012 679 687
17. M. Braendengen, K.M. Tveit, A. Berglund, E. Birkemeyer, G. Frykolm, and L. Pahlman Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in non resectable rectal cancer J Clin Oncol 26 2008 3687 3694
18. P. Khrizman, J.C. Niland, and A. ter Veer Postoperative adjuvant chemotherapy (CTX) use in patients (Pts) with stage II/III rectal cancer treated with neoadjuvant therapy: A National Comprehensive Cancer Network (NCCN) analysis J Clin Oncol 29 2011 [abstr 3515]
19. L. Cionini, A. Sainato, and A. DePaoli Final results of a randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer Radiother Oncol 96 2010 S113 [abst. 299]
20. L. Collette, and J.F. Bosset Adjuvant chemotherapy following neoadjuvant therapy in rectal cancer: the type of neoadjuvant therapy (chemoradiation or radiotherapy) may be important for selection of patients J Clin Oncol 26 2008 507 508 (in reply to Fietkau R and Klautke G)
21. L. Collette, and J.F. Bosset Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group J Clin Oncol 25 2007 4379 4386
22. J.F. Bosset, and C. Gilles Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study Lancet Oncol 15 2014 184 190
23. Hong YS, Nam B, Kim K, et al. Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemotherapy: updated results of 3-year disease-free survival from a randomized phase II study (The ADORE). In: ASCO Annual Meeting; June 2, 2014.
24. C. Capirci, V. Valentini, and L. Cionini Prognostic value of complete pathologic response after neoadjuvant therapy in locally advanced rectal cancer: long term analysis of 566 ypCR patients Int J Rad Oncol Biol Phys 72 2008 99 107
25. R. Fietkau, M. Barten, and G. Klautke Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer Dis Colon Rectum 49 2006 Sep 1284 1292
26. C. Rödel, Martus, and T. Papadoupolo Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer J Clin Oncol 23 2005 Dec 8688 8696
27. Breugom AJ, van den Broek CBM, Van Gijn W et al. The value of adjuvant chemotherapy in rectal cancer patients after preoperative radiotherapy or chemoradiation follow by TME surgery. The PROCTOR/SCRIPT study. In: European cancer Congress; 2013 [abst. 1].
28. J.H. Cornelis, van de Velde, and Petra G. Boelens EURECCA colorectal: Multidisciplinary management: European Consensus conference colon & rectum Eur J Cancer 50 2014 1.e1 1.e34
29. H. Lee Jong, and S. Jang Hong Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: Pooled analysis of KROG 10-01 and 11-02 Radiother Oncol 113 2014 18 23
30. J.P. Maarten Burbach, and A. Marie den Harder Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis Radiother Oncol 113 2014 1 9
31. M. Overgaard, J. Overgaard, and A. Sell Dose-response relationship for radiation therapy of recurrent, residual, and primarily inoperable colorectal cancer Radiother Oncol 1 1984 217 225
32. B. Engels, N. Platteaux, R. Van den Begin, T. Gevaert, A. Sermeus, and G. Storme Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome Radiother Oncol 110 2014 155 159
33. J. Sakamoto, C. Hamada, and S. Yoshida An individual patients data metanalysis of adjuvant therapy with uracil tegafur (UFT) in patients with curatively resected rectal cancer Br J Cancer 96 2007 1170 1177
34. J.P. Gerard, D. Azria, and S. Gourgou-Bourgade Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/045-Prodige-2 J Clin Oncol 28 2010 1638 1644
35. C. Aschele, L. Cionini, and S. Lonardi Primary rumour response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR 01 randomized phase III trial J. Clin Oncol 29 2011 2773 2780
36. M.S. Roh, G.A. Yothers, and M.J. O'Connel The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABO R-04 Proc Am Soc Clin Oncol 29 2010 [abst. 3503]
37. I. Chau, G. Brown, and D. Cunnigham Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer J. Clin Oncol 24 2006 668 674
38. A. Dewdney, D. Cunnighanm, and J. Tabernero Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high risk rectal cancer (EXPERT-C) J Clin Oncol 30 2012 1620 1627
39. Seung-Gu Yeo, Jae Hwan Oh, and Dae Yong Kim Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01) Int J Rad Oncol Biol Phys 2012
40. C. Fernandez-Martos, C. Pericay, and J. Aparicio PhaseII randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging defined locally advanced rectal cancer: Group of Cancer de Recto 3 study J Clin Oncol 28 2010 859 865
41. Vivaldi C, Morvillo M, Sainato A, et al. Preliminary safety analysis of a phase II trial with FOLFOXIRI and bevacizumab (BV) followed by chemo-radiotherapy (CRT) and BV in locally advanced rectal cancer (LARC) (TRUST trial). Tumori 2013;14:S11-A18.